

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Asymchem Laboratories (Tianjin) Co., Ltd.

凱萊英醫藥集團(天津)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6821)

VOLUNTARY ANNOUNCEMENT

This is a voluntary announcement made by Asymchem Laboratories (Tianjin) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide its shareholders and potential investors with information in relation to the latest developments regarding the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company entered into an investment agreement with the Management Committee of Taixing Economic Development Zone, Jiangsu Province on September 26, 2022 in relation to the transfer of land with a total area of approximately 400 mu (the final area is subject to the real property certificates issued by the competent authorities after actual survey) in the Jiangsu Taixing Economic Development Zone (the “**Project Land**”) to the Group and the investment and construction of a “base project for the integrated R&D and production of biological medicines” (together with the “**Project Land**”, collectively referred to as the “**Project**”) by the Group. Jiangsu Taixing Economic Development Zone is a provincial development zone, and also one of the 15 major parks developed by Jiangsu Province along the Yangtze River.

The construction of the Project is for the R&D and production of chemical raw materials and drug substance of small molecule CDMO, as well as the expansion of constructions of small molecule CDMO drug products, drug R&D, the promotion and application of new technologies and other projects, with estimated total investment amount of approximately RMB4,000,000,000 to RMB5,000,000,000 (or the equivalent in foreign currency, subject to the specific agreement of the subsequent land transfer agreement and other related agreements to be signed) and the estimated source of funds includes our cash in hand or self-raised funds, both of which will be determined upon the finalization of the Project plan. The Project may be designed as a whole, implemented in phases and put into production in batches. The Group may, subject to the negotiation with the Management Committee of Taixing Economic Development Zone, Jiangsu Province, make adjustments and changes to the actual investment and construction, industry types, investment scale, investment subject, etc., of the Project, in accordance with the relevant circumstances and changes in markets, policies, investment environment, and other factors.

The Board would like to emphasize that the detailed terms and conditions of the Project Land shall be stipulated in the separately signed agreement, and the existing investment agreement is not legally binding. As of the date of this announcement, the Company has not obtained any legally valid qualifications or certificates for the implementation of the Project, and the implementation of the Project is subject to the completion of the approval procedures with the relevant competent authorities. Therefore, there is no guarantee that the Project will be materialized. The Company will make further announcements on the Project in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited when appropriate.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
Asymchem Laboratories (Tianjin) Co., Ltd.
Dr. Hao Hong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Tianjin, September 26, 2022

As of the date of this announcement, the Board of Directors of the Company comprises Dr. Hao Hong as the Chairman of the Board of Directors and executive Director, Ms. Yang Rui, Mr. Zhang Da and Mr. Hong Liang as executive Directors, Dr. Ye Song and Ms. Zhang Ting as non-executive Directors, and Ms. Zhang Kun, Mr. Wang Qingsong and Mr. Lee, Kar Chung Felix as independent non-executive Directors.